Details of the Drug

General Information of Drug (ID: DMIY6DB)

Drug Name

Verteporfin

Synonyms

Visudyne (TN)

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Approved	[1]

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski):
4

Molecular Weight

1437.6

Topological Polar Surface Area

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 5 - 6 hours [2]
Metabolism: The drug is metabolized via the liver and plasma esterases [3]

Chemical Identifiers

Formula: C82H84N8O16
IUPAC Name: 3-[(23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid;3-[(23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-5-yl]propanoic acid
Canonical SMILES: CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C
InChI: InChI=1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/t2*38-,41+/m00/s1
InChIKey: NJLRKAMQPVVOIU-IDLGWYNRSA-N

Cross-matching ID

PubChem CID: 11980904
DrugBank ID: DB00460
TTD ID: D0I3XG
VARIDT ID: DR00209

Molecular Interaction Atlas of This Drug

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
ATP-binding cassette sub-family B member 6 (ABCB6)	DTF9Y2V	ABCB6_HUMAN	Substrate	[4]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Verteporfin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Tazarotene	DM8SMD1	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Tazarotene.	Psoriasis [EA90]	[15]
-----------

Coadministration of a Drug Treating the Disease Different from Verteporfin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Tretinoin	DM49DUI	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Tretinoin.	Acne vulgaris [ED80]	[15]
Isotretinoin	DM4QTBN	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Isotretinoin.	Acne vulgaris [ED80]	[15]
Sarecycline	DMLZNIQ	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Sarecycline .	Acne vulgaris [ED80]	[15]
Trifarotene	DMOL793	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Trifarotene.	Acne vulgaris [ED80]	[15]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Glibenclamide.	Acute diabete complication [5A2Y]	[15]
Tolazamide	DMIHRNA	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Tolazamide.	Acute diabete complication [5A2Y]	[15]
Glipizide	DMZA5PQ	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Glipizide.	Acute diabete complication [5A2Y]	[15]
Voriconazole	DMAOL2S	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Voriconazole.	Aspergillosis [1F20]	[15]
Ofloxacin	DM0VQN3	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[15]
Trovafloxacin	DM6AN32	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[15]
Sparfloxacin	DMB4HCT	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Gemifloxacin	DMHT34O	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Oxytetracycline	DMOVH1M	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Oxytetracycline.	Bacterial infection [1A00-1C4Z]	[15]
Omadacycline	DMR2J95	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Omadacycline.	Bacterial infection [1A00-1C4Z]	[15]
Levofloxacin	DMS60RB	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Minocycline	DMVN5OH	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Minocycline.	Bacterial infection [1A00-1C4Z]	[15]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Tetracycline	DMZA017	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Tetracycline.	Bacterial infection [1A00-1C4Z]	[15]
Lapatinib	DM3BH1Y	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Lapatinib.	Breast cancer [2C60-2C6Y]	[15]
Demeclocycline	DMZEPFJ	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Demeclocycline.	Bronchitis [CA20]	[15]
Panitumumab	DMQPD1F	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Panitumumab.	Colorectal cancer [2B91]	[15]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Ethacrynic acid.	Essential hypertension [BA00]	[15]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Benzthiazide.	Essential hypertension [BA00]	[15]
Avapritinib	DMK2GZX	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[15]
Acetazolamide	DM1AF5U	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Acetazolamide.	Glaucoma [9C61]	[15]
Chlorothiazide	DMLHESP	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Chlorothiazide.	Heart failure [BD10-BD1Z]	[15]
Furosemide	DMMQ8ZG	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Furosemide.	Heart failure [BD10-BD1Z]	[15]
Bumetanide	DMRV7H0	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Bumetanide.	Heart failure [BD10-BD1Z]	[15]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[15]
Simeprevir	DMLUA9D	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Simeprevir.	Hepatitis virus infection [1E50-1E51]	[15]
Tipranavir	DM8HJX6	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Tipranavir.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Indapamide	DMGN1PW	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Indapamide.	Hypertension [BA00-BA04]	[15]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Trichlormethiazide.	Hypertension [BA00-BA04]	[15]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[15]
Pirfenidone	DM6VZFQ	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Pirfenidone.	Idiopathic interstitial pneumonitis [CB03]	[15]
TP-434	DM5A31S	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and TP-434.	Infectious gastroenteritis/colitis [1A40]	[15]
Propiomazine	DMKY8V1	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Propiomazine.	Insomnia [7A00-7A0Z]	[15]
Alitretinoin	DMME8LH	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Alitretinoin.	Kaposi sarcoma [2B57]	[15]
Methotrexate	DM2TEOL	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Methotrexate.	Leukaemia [2A60-2B33]	[15]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Porfimer Sodium.	Lung cancer [2C25]	[16]
Erlotinib	DMCMBHA	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Erlotinib.	Lung cancer [2C25]	[15]
Alectinib	DMP1I6Y	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Alectinib.	Lung cancer [2C25]	[15]
BIBW 2992	DMTKD7Q	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and BIBW 2992.	Lung cancer [2C25]	[15]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Sulphadoxine.	Malaria [1F40-1F45]	[15]
Vemurafenib	DM62UG5	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Vemurafenib.	Melanoma [2C30]	[15]
Dabrafenib	DMX6OE3	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Dabrafenib.	Melanoma [2C30]	[15]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Methoxsalen.	Mycosis fungoides [2B01]	[17]
Imatinib	DM7RJXL	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Imatinib.	Myeloproliferative neoplasm [2A20]	[15]
Promethazine	DM6I5GR	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Promethazine.	Nausea/vomiting [MD90]	[15]
Metolazone	DMB39LO	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Metolazone.	Oedema [MG29]	[15]
Polythiazide	DMCH80F	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Polythiazide.	Oedema [MG29]	[15]
Valdecoxib	DMAY7H4	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Valdecoxib.	Osteoarthritis [FA00-FA05]	[15]
Bicalutamide	DMZMSPF	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Bicalutamide.	Prostate cancer [2C82]	[15]
Levomepromazine	DMIKFEL	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[15]
Triflupromazine	DMKFQJP	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Triflupromazine.	Psychotic disorder [6A20-6A25]	[15]
Gatifloxacin	DMSL679	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[15]
Celecoxib	DM6LOQU	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Celecoxib.	Rheumatoid arthritis [FA20]	[15]
Sulfasalazine	DMICA9H	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Sulfasalazine.	Rheumatoid arthritis [FA20]	[15]
Mesoridazine	DM2ZGAN	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Mesoridazine.	Schizophrenia [6A20]	[15]
Thioridazine	DM35M8J	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Thioridazine.	Schizophrenia [6A20]	[15]
Perphenazine	DMA4MRX	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Perphenazine.	Schizophrenia [6A20]	[15]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Chlorpromazine.	Schizophrenia [6A20]	[15]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Trifluoperazine.	Schizophrenia [6A20]	[15]
Tigecycline	DMLE7IO	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Tigecycline.	Skin and skin-structure infection [1F28-1G0Z]	[15]
Imiquimod	DM1TMA3	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Imiquimod.	Skin cancer [2C30-2C37]	[15]
Vandetanib	DMRICNP	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[15]
Tolbutamide	DM02AWV	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[15]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[15]
Cinoxacin	DM4EWNS	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Cinoxacin.	Urinary tract infection [GC08]	[15]
Sulfamethizole	DMGCHDS	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Sulfamethizole.	Urinary tract infection [GC08]	[15]
Nalidixic acid	DMRM0JV	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Nalidixic acid.	Urinary tract infection [GC08]	[15]
Enoxacin	DMYTE6L	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Enoxacin.	Urinary tract infection [GC08]	[15]
Methdilazine	DMAUHQX	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[15]
Trimeprazine	DMEMV9D	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[15]
Amiodarone	DMUTEX3	Moderate	Increased risk of photosensitivity reactions by the combination of Verteporfin and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[15]
-----------


⏷ Show the Full List of 78 DDI Information of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	Efficient purification and reconstitution of ATP binding cassette transporter B6 (ABCB6) for functional and structural studies. J Biol Chem. 2013 Aug 2;288(31):22658-69.
5	The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70.
6	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
7	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
8	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
9	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
10	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
11	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
12	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
13	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
14	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
17	Cerner Multum, Inc. "Australian Product Information.".